期刊文献+

The Co_3O_4 nanosheet array as support for MoS_2 as highly efficient electrocatalysts for hydrogen evolution reaction 被引量:4

The Co_3O_4 nanosheet array as support for MoS_2 as highly efficient electrocatalysts for hydrogen evolution reaction
在线阅读 下载PDF
导出
摘要 The electrochemical hydrogen evolution reaction(HER) on a non-precious electrocatalyst in an alkaline environment is of essential importance for future renewable energy. The design of advanced electrocatalysts for HER is the most important part to reduce the cost and to enhance the efficiency of water splitting. MoSis considered as one of the most promising electrocatalysts to replace the precious Pt catalyst.Herein, for the first time, we have successfully loaded MoSelectrocatalysts onto the CoOnanosheet array to catalyze HER with a low onset potential of6 mV. The high hydrogen evolution activity of MoSsupported on the CoOnanosheet array may be attributed to the increased active sites and the electronic interactions between MoSand CoO. The electrochemical hydrogen evolution reaction(HER) on a non-precious electrocatalyst in an alkaline environment is of essential importance for future renewable energy. The design of advanced electrocatalysts for HER is the most important part to reduce the cost and to enhance the efficiency of water splitting. MoS_2 is considered as one of the most promising electrocatalysts to replace the precious Pt catalyst.Herein, for the first time, we have successfully loaded MoS_2 electrocatalysts onto the Co_3O_4 nanosheet array to catalyze HER with a low onset potential of ~76 mV. The high hydrogen evolution activity of MoS_2 supported on the Co_3O_4 nanosheet array may be attributed to the increased active sites and the electronic interactions between MoS_2 and Co_3O_4.
出处 《Journal of Energy Chemistry》 SCIE EI CAS CSCD 2017年第6期1136-1139,共4页 能源化学(英文版)
基金 support from the National Natural Science Foundation of China (51402100 and 21573066) the Provincial Natural Science Foundation of Hunan (2016JJ1006 and 2016TP1009)
关键词 MoS_2 Co_3O_4 SUPPORT ELECTROCATALYST Hydrogen evolution reaction MoS_2 Co_3O_4 Support Electrocatalyst Hydrogen evolution reaction
  • 相关文献

参考文献3

二级参考文献91

  • 1Uriel A J, Fiere D S, Carriero D C, et al. An on-going out break of acute HCV in HIV infected men in New York city Rates of spontaneous clearance and treatment responses[J].Hepatology, 2008, 48(4Suppl): 531A.
  • 2Bruno S, Hadziyannis S J, Shiffman M L, et al. Are there differences in treatment outcomes between HCV genotype 2 and 3 patients with advanced fibrosis treated with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) ?[J]. Hepatology, 2008, 48(4Suppl): 860A.
  • 3Oze T, Hiramatsu N, Yokushijin T, et al. Extended treatment with peginterferon alfa-2b and ribavirin combination therapy can suppress the relapse rate after treatment of chronic hepatitis C genotype 1 patients with late viral response[J]. Hepatology, 2008, 48(4Suppl): 853A.
  • 4Hayashi K, Katano Y, Ishigami M, et al. Mutations in the core and NS5A region of hepatitis C virus genotype lb and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy[J]. Hepatology, 2008, 48(4Suppl) : 848A.
  • 5Elgouhari H M, Cesario K B, Lopez R, etal. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive PTS[J].Hepatology, 2008, 48(4Suppl): 383A.
  • 6Romero-Gomez M, Diago M, Andrade R J, etal. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naive genotype 1 chronic hepatitis C patients with insulin resistance(TRIC-1 ): Final results of randomized and doubleblinded trial[J]. 2008, 48(4Suppl) : 380A.
  • 7Marotta P, Cooper C, Wong D K, et al. Impact of advanced fibrosis and cirrhosis on sustained virologic response of HCV Gl-infected patients: Results of the Canadian power program [J]. Hepatology, 2008, 48(4Suppl):849A.
  • 8Schwarz K, Gonzalez-Peralta R P, Murray K F, et al. Pegimerferon with or without ribavirin for chronic hepatitis C in children and adolescents: Final results of the PEDS-C trial[J].Hepatology, 2008, 48(4Suppl):418A.
  • 9Pawlowska M, Pilarczyk M, Halota W, et al. Virologic re- sponse to treatment with pegylated interferon alfa-2h and ribavirin chric hepatitis C in children[J]. Hepatology, 2008, 48 (4Suppl) : 855A.
  • 10Wang K, Lawal A A, Majchrowicz M, et al. Pharmacokinetics of ribavirin in patients with renal impairment or end-stage renal disease and chronic hepatitis C during treatment with peginterferon alfa-2a (40KD) (PEGASYS) and RBV ( COPEGUS) [J]. Hepatology, 2008, 48(4Suppl): 1142A.

共引文献9

同被引文献6

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部